查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1570846

感染疾病物市场：副产品、病原体、作用机制、给药途径和最终用户 - 2025-2030 年全球预测

Anti-infectives Market by Product (Biologics, Drugs, Vaccines), Pathogen (Bacterial Infections, Fungal Infections, Parasitic Infections), Mechanism Of Action, Route Of Administration, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年感染疾病物市值为1,257.8亿美元，预计2024年将达到1,314.3亿美元，复合年增长率为5.12%，预计2030年将达到1,784.3亿美元。

感染疾病物市场包括多种对抗细菌、病毒、真菌和寄生虫感染疾病的产品。此类别包括抗生素、抗病毒药物、抗真菌药物和抗寄生虫药。感染疾病物的需求在于它们在医疗保健中的重要作用，它们对于治疗感染疾病、预防疾病传播和降低死亡率至关重要。这些药物用于医院、门诊诊所和居家医疗机构，以满足人类和动物的需求。该市场面向从儿童到老年人的广泛人群，并支持製药和生物技术等众多行业。

主要市场统计
基准年[2023] 1257.8亿美元
预测年份 [2024] 1314.3亿美元
预测年份 [2030] 1784.3亿美元
复合年增长率（%） 5.12%

推动市场开拓的关键因素包括感染疾病流行、抗菌素抗药性意识的增强以及药物开发技术的进步。特别是由于多重抗药性病原体，对新型感染疾病物的需求不断增长，这带来了巨大的商机。公司可以透过投资新疗法的研发、探索与生物技术公司的合作伙伴关係以及利用人工智慧主导的药物发现流程来利用这些前景。由于医疗基础设施的扩大和医疗成本的上升，新兴国家也代表着利润丰厚的市场。

然而，市场面临阻碍开发新药步伐的多项挑战，包括严格的监管和不断上升的研发成本。市场相关人员还必须应对抗菌素抗药性的复杂挑战，这需要持续创新和策略投资。最佳的创新途径包括开发窄频谱药物、联合治疗以及根据个人基因谱量身定制的个人化抗感染疾病治疗。

总之，感染疾病物市场潜力巨大，但成长需要将策略重点放在克服监管障碍、提高成本效率和促进创新。寻求与学术和研究机构的合作可以提供有价值的见解，并有助于将创新开拓推向市场，帮助企业在这个充满活力的市场环境中实现永续成长。

市场动态：揭示快速发展的感染疾病物市场的关键市场洞察

供需的动态交互作用正在改变感染疾病物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，以及如何减轻消费行为及其对製造成本的影响及其对采购趋势的影响。

波特五力：驾驭感染疾病物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点，避免潜在的挑战，确保更强大的市场地位。

PESTLE分析：了解感染疾病物市场的外部影响

外部宏观环境因素在塑造感染疾病物市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解感染疾病物市场竞争状况

感染疾病物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵感染疾病物市场供应商的绩效评估

FPNV定位矩阵是评估感染疾病物市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划感染疾病物市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，感染疾病物市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告提供了涵盖关键焦点细分市场的全面市场分析。

1. 市场渗透率：对当前市场环境的详细回顾。

2. 市场开拓：辨识新兴市场的成长机会，评估现有产业的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检视市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 新兴国家医疗基础设施扩大加速感染疾病物市场成长
      • 严格的监管指南，促进有效抗感染药物的开发和核准
      • 製药业策略合作与伙伴关係加速抗感染药物研发
      • 不断上涨的医疗成本和改善医疗设施的使用正在推动感染疾病物的需求
    • 抑制因素
      • 抗感染药物市场产品生命週期短、开发成本高，投资收益率低
      • 患者不遵守规定的抗感染治疗会导致治疗结果不佳和抗药性增加
    • 机会
      • 基于患者特定因素的标靶抗感染治疗的个人化医疗方法的发展
      • 利用人工智慧和机器学习快速辨识新的抗感染化合物
      • 投资先进生物研究以开发下一代抗菌疗法
    • 任务
      • 不断上升的研发成本限制了感染疾病物的创新和新药发现
      • 市场进入障碍高，阻碍小企业有效竞争
  • 市场区隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章感染疾病物市场：副产品

  • 介绍
  • 生技药品
    • 干扰素
    • 单株抗体
    • 重组蛋白
  • 药品
    • 静脉
    • 口服液
    • 锭剂
  • 疫苗
    • 细菌疫苗
    • 病毒疫苗

第七章感染疾病物市场：依病原体分类

  • 介绍
  • 细菌感染疾病
    • 大肠桿菌
    • 金黄色葡萄球菌
  • 霉菌感染疾病
    • 曲菌属
    • 念珠菌属
  • 寄生虫感染疾病
    • 利什曼原虫症
    • 疟疾
  • 病毒感染
    • 肝炎
    • HIV

第八章感染疾病物市场：按作用机制

  • 介绍
  • 细胞壁合成抑制剂
  • 核酸合成抑制剂
  • 蛋白质合成抑制剂

第九章感染疾病物市场：依给药途径

  • 介绍
  • 静脉
  • 口服
  • 局部的

第十章感染疾病物市场：依最终用户分类

  • 介绍
  • 诊所
  • 居家医疗
  • 医院

第十一章 美洲感染疾病物市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太感染疾病物市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章 欧洲、中东和非洲感染疾病物市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议
Product Code: MRR-1A1A064C0031

The Anti-infectives Market was valued at USD 125.78 billion in 2023, expected to reach USD 131.43 billion in 2024, and is projected to grow at a CAGR of 5.12%, to USD 178.43 billion by 2030.

The anti-infectives market encompasses a broad range of products designed to combat infections caused by bacteria, viruses, fungi, and parasites. This category includes antibiotics, antivirals, antifungals, and antiparasitic agents. The necessity of anti-infectives lies in their critical role in healthcare, as they are essential for treating infections, preventing disease spread, and reducing mortality. These agents find applications in hospitals, outpatient clinics, and home healthcare settings, catering to both human and veterinary needs. The market serves a wide demographic, from pediatric to geriatric populations, and supports numerous industries, including pharmaceuticals and biotechnology.

KEY MARKET STATISTICS
Base Year [2023] USD 125.78 billion
Estimated Year [2024] USD 131.43 billion
Forecast Year [2030] USD 178.43 billion
CAGR (%) 5.12%

Market growth is primarily driven by factors such as the increasing prevalence of infectious diseases, growing awareness of antimicrobial resistance, and advances in drug development technologies. The rising need for new classes of anti-infectives, especially due to multidrug-resistant pathogens, presents significant opportunities. Companies can capitalize on these prospects by investing in R&D for novel therapeutics, exploring partnerships with biotechnology firms, and leveraging AI-driven drug discovery processes. Emerging economies also present lucrative markets due to their expanding healthcare infrastructure and rising healthcare expenditure.

However, the market faces several challenges, including stringent regulatory mandates and the high cost of R&D, which can hinder the pace of new drug development. Market players must also navigate the complexities of antimicrobial resistance, which requires continuous innovation and strategic investment. The best avenues for innovation include development of narrow-spectrum agents, combination therapies, and personalized anti-infective treatments tailored to individual genetic profiles.

In conclusion, while the anti-infectives market holds expansive potential, growth demands strategic focus on overcoming regulatory hurdles, improving cost efficiency, and fostering innovation. Pursuing collaborations with academic and research institutions can provide valuable insights and boost the development of groundbreaking solutions, positioning companies for sustainable growth in this dynamic market landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anti-infectives Market

The Anti-infectives Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Expansion of healthcare infrastructure in emerging economies fueling the anti-infectives market growth
    • Stringent regulatory guidelines promoting the development and approval of effective anti-infective medications
    • The pharmaceutical industry's strategic collaborations and partnerships to boost anti-infective drug discovery
    • Increasing healthcare expenditure and better access to medical facilities driving demand for anti-infectives
  • Market Restraints
    • Lower return on investment due to short product lifecycles and high cost of development in anti-infective market
    • Patient non-adherence to prescribed anti-infective regimens leading to suboptimal treatment outcomes and increased resistance
  • Market Opportunities
    • Growth of personalized medicine approaches for targeted anti-infective treatments based on patient-specific factors
    • Leveraging artificial intelligence and machine learning for rapid identification of novel anti-infective compounds
    • Investing in advanced biotechnological research for development of next-generation anti-microbial therapies
  • Market Challenges
    • Escalating research and development costs limiting innovation and new drug discoveries in anti-infectives
    • High market entry barriers preventing small and medium-sized enterprises from competing effectively

Porter's Five Forces: A Strategic Tool for Navigating the Anti-infectives Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anti-infectives Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anti-infectives Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anti-infectives Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anti-infectives Market

A detailed market share analysis in the Anti-infectives Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anti-infectives Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anti-infectives Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anti-infectives Market

A strategic analysis of the Anti-infectives Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anti-infectives Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Allergan plc, Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Cubist Pharmaceuticals, Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Shionogi & Co., Ltd., Takeda Pharmaceutical Company Limited, and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the Anti-infectives Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Biologics, Drugs, and Vaccines. The Biologics is further studied across Interferons, Monoclonal Antibodies, and Recombinant Proteins. The Drugs is further studied across Intravenous, Oral Liquids, and Tablets. The Vaccines is further studied across Bacterial Vaccines and Viral Vaccines.
  • Based on Pathogen, market is studied across Bacterial Infections, Fungal Infections, Parasitic Infections, and Viral Infections. The Bacterial Infections is further studied across Escherichia Coli and Staphylococcus Aureus. The Fungal Infections is further studied across Aspergillus and Candida. The Parasitic Infections is further studied across Leishmaniasis and Malaria. The Viral Infections is further studied across Hepatitis and HIV.
  • Based on Mechanism Of Action, market is studied across Cell Wall Synthesis Inhibitors, Nucleic Acid Synthesis Inhibitors, and Protein Synthesis Inhibitors.
  • Based on Route Of Administration, market is studied across Intravenous, Oral, and Topical.
  • Based on End User, market is studied across Clinics, Homecare, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Expansion of healthcare infrastructure in emerging economies fueling the anti-infectives market growth
      • 5.1.1.2. Stringent regulatory guidelines promoting the development and approval of effective anti-infective medications
      • 5.1.1.3. The pharmaceutical industry's strategic collaborations and partnerships to boost anti-infective drug discovery
      • 5.1.1.4. Increasing healthcare expenditure and better access to medical facilities driving demand for anti-infectives
    • 5.1.2. Restraints
      • 5.1.2.1. Lower return on investment due to short product lifecycles and high cost of development in anti-infective market
      • 5.1.2.2. Patient non-adherence to prescribed anti-infective regimens leading to suboptimal treatment outcomes and increased resistance
    • 5.1.3. Opportunities
      • 5.1.3.1. Growth of personalized medicine approaches for targeted anti-infective treatments based on patient-specific factors
      • 5.1.3.2. Leveraging artificial intelligence and machine learning for rapid identification of novel anti-infective compounds
      • 5.1.3.3. Investing in advanced biotechnological research for development of next-generation anti-microbial therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Escalating research and development costs limiting innovation and new drug discoveries in anti-infectives
      • 5.1.4.2. High market entry barriers preventing small and medium-sized enterprises from competing effectively
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anti-infectives Market, by Product

  • 6.1. Introduction
  • 6.2. Biologics
    • 6.2.1. Interferons
    • 6.2.2. Monoclonal Antibodies
    • 6.2.3. Recombinant Proteins
  • 6.3. Drugs
    • 6.3.1. Intravenous
    • 6.3.2. Oral Liquids
    • 6.3.3. Tablets
  • 6.4. Vaccines
    • 6.4.1. Bacterial Vaccines
    • 6.4.2. Viral Vaccines

7. Anti-infectives Market, by Pathogen

  • 7.1. Introduction
  • 7.2. Bacterial Infections
    • 7.2.1. Escherichia Coli
    • 7.2.2. Staphylococcus Aureus
  • 7.3. Fungal Infections
    • 7.3.1. Aspergillus
    • 7.3.2. Candida
  • 7.4. Parasitic Infections
    • 7.4.1. Leishmaniasis
    • 7.4.2. Malaria
  • 7.5. Viral Infections
    • 7.5.1. Hepatitis
    • 7.5.2. HIV

8. Anti-infectives Market, by Mechanism Of Action

  • 8.1. Introduction
  • 8.2. Cell Wall Synthesis Inhibitors
  • 8.3. Nucleic Acid Synthesis Inhibitors
  • 8.4. Protein Synthesis Inhibitors

9. Anti-infectives Market, by Route Of Administration

  • 9.1. Introduction
  • 9.2. Intravenous
  • 9.3. Oral
  • 9.4. Topical

10. Anti-infectives Market, by End User

  • 10.1. Introduction
  • 10.2. Clinics
  • 10.3. Homecare
  • 10.4. Hospitals

11. Americas Anti-infectives Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Anti-infectives Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Anti-infectives Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Allergan plc
  • 3. Amgen Inc.
  • 4. Astellas Pharma Inc.
  • 5. AstraZeneca PLC
  • 6. Bayer AG
  • 7. Bristol-Myers Squibb Company
  • 8. Cubist Pharmaceuticals, Inc.
  • 9. Eli Lilly and Company
  • 10. F. Hoffmann-La Roche AG
  • 11. Gilead Sciences, Inc.
  • 12. GlaxoSmithKline plc
  • 13. Johnson & Johnson
  • 14. Merck & Co., Inc.
  • 15. Novartis AG
  • 16. Pfizer Inc.
  • 17. Sanofi S.A.
  • 18. Shionogi & Co., Ltd.
  • 19. Takeda Pharmaceutical Company Limited
  • 20. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. ANTI-INFECTIVES MARKET RESEARCH PROCESS
  • FIGURE 2. ANTI-INFECTIVES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTI-INFECTIVES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ANTI-INFECTIVES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. ANTI-INFECTIVES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTI-INFECTIVES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTI-INFECTIVES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTI-INFECTIVES MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ORAL LIQUIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY VIRAL VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ESCHERICHIA COLI, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ASPERGILLUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY CANDIDA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY LEISHMANIASIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY MALARIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HIV, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY CELL WALL SYNTHESIS INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY NUCLEIC ACID SYNTHESIS INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PROTEIN SYNTHESIS INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. CANADA ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 90. CANADA ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 97. CANADA ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 98. CANADA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. CANADA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. MEXICO ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. MEXICO ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 102. MEXICO ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 103. MEXICO ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 104. MEXICO ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 105. MEXICO ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 106. MEXICO ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 107. MEXICO ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 108. MEXICO ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 109. MEXICO ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 110. MEXICO ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. MEXICO ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 112. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 113. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 114. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 115. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 116. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 117. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 118. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 119. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 120. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 121. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 122. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 138. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 139. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 140. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 141. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 142. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 143. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 144. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 146. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 147. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 148. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 150. CHINA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 151. CHINA ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 152. CHINA ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 153. CHINA ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 154. CHINA ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 155. CHINA ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 156. CHINA ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 157. CHINA ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 158. CHINA ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 159. CHINA ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 160. CHINA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. CHINA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 162. INDIA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 163. INDIA ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 164. INDIA ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 165. INDIA ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 166. INDIA ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 167. INDIA ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 168. INDIA ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 169. INDIA ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 170. INDIA ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 171. INDIA ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 172. INDIA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. INDIA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 174. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 175. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 176. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 177. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 178. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 179. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 180. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 181. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 182. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 183. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 184. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 186. JAPAN ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 187. JAPAN ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 188. JAPAN ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 189. JAPAN ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 190. JAPAN ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 191. JAPAN ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 192. JAPAN ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 193. JAPAN ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 194. JAPAN ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 195. JAPAN ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 196. JAPAN ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 197. JAPAN ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 198. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 199. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 200. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 201. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 202. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 203. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 204. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 205. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 206. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 207. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 208. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 209. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 210. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 211. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 212. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 213. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 214. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 215. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 216. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 217. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 218. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 219. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 220. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 221. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 222. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 223. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 224. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 225. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 226. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 227. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 228. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 229. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 230. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 231. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 232. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 233. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 234. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 235. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 236. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 237. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 238. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 246. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 247. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 248. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 249. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 250. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 251. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 252. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 253. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 254. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 255. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 256. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 257. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 258. THAILAND ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 259. THAILAND ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 260. THAILAND ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 261. THAILAND ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 262. THAILAND ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 263. THAILAND ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 264. THAILAND ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 265. THAILAND ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 266. THAILAND ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 267. THAILAND ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 268. THAILAND ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 269. THAILAND ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 270. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 271. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 272. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 273. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 274. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 275. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 276. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 277. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 278. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 279. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 280. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 281. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 295. DENMARK ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 296. DENMARK ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 297. DENMARK ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 298. DENMARK ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 299. DENMARK ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 300. DENMARK ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 301. DENMARK ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 302. DENMARK ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 303. DENMARK ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 304. DENMARK ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 305. DENMARK ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 306. DENMARK ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 307. EGYPT ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 308. EGYPT ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 309. EGYPT ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 310. EGYPT ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 311. EGYPT ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 312. EGYPT ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 313. EGYPT ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 314. EGYPT ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 315. EGYPT ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 316. EGYPT ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 317. EGYPT ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 318. EGYPT ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 319. FINLAND ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 320. FINLAND ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 321. FINLAND ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 322. FINLAND ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 323. FINLAND ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 324. FINLAND ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 325. FINLAND ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 326. FINLAND ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 327. FINLAND ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 328. FINLAND ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 329. FINLAND ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 330. FINLAND ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 331. FRANCE ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 332. FRANCE ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 333. FRANCE ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 334. FRANCE ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 335. FRANCE ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 336. FRANCE ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 337. FRANCE ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 338. FRANCE ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 339. FRANCE ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 340. FRANCE ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 341. FRANCE ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 342. FRANCE ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 343. GERMANY ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 344. GERMANY ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 345. GERMANY ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 346. GERMANY ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 347. GERMANY ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 348. GERMANY ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 349. GERMANY ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 350. GERMANY ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 351. GERMANY ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 352. GERMANY ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 353. GERMANY ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 354. GERMANY ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 355. ISRAEL ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 356. ISRAEL ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 357. ISRAEL ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 358. ISRAEL